Literature DB >> 35748596

Determination of Patient Adherence for Duloxetine in Urine.

Haley A Mulder1, Greg L McIntire2, Frank N Wallace2, Justin L Poklis3.   

Abstract

Duloxetine, known by its brand name, CymbaltaTM, is a selective serotonin and norepinephrine reuptake inhibitor used to treat major depressive disorders. Determination of patient compliance for duloxetine is typically determined through medication possession ratio (MPR) or plasma concentrations. The purpose of this paper was to characterize normal urinary duloxetine concentrations in patients prescribed duloxetine to monitor patient adherence. Patient data collected from routine screens for duloxetine concentrations in urine were included in this study. Inclusion criteria consisted of patients who were prescribed duloxetine and (i) tested positive for duloxetine, (ii) tested negative for illicit substances and (iii) included creatinine, age and duloxetine dose administered. Of the 5,592 patient urines screened, 2,004 of the results fit into the inclusion criteria. Positive urine concentrations of duloxetine ranged from 50 to 2,722 ng/mL. Duloxetine urine concentrations were normalized to creatinine and dose further characterized by sex, age, body mass index (BMI) and dose in milligrams. Sample distribution included urines collected from 1,487 females and 517 males. The age range of the specimen donors was between 15 and 90 years old with an average age of 52. BMI levels ranged from 13.9 (underweight) to 88.1 (obese), with the average BMI being 33.5. The most common dose of duloxetine prescribed was a daily, oral dose of 60 mg. Analysis of the normalized, transformed creatinine concentrations showed that there was a significant statistical difference (P < 0.05) in the urinary duloxetine concentrations by sex and by dose (mg). Female patients further showed a statistical difference in urinary duloxetine concentration in age groups 18-64 and 64 and older. By characterizing urinary duloxetine concentrations in patients prescribed the medication, normalized distributions of data ranges have been established. These data ranges for urinary duloxetine concentrations can be used to determine patient compliance with duloxetine in routine, clinical samples.
© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35748596      PMCID: PMC9564183          DOI: 10.1093/jat/bkac043

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.220


  20 in total

1.  A Dilute-and-Shoot LC-MS Method for Quantitating Opioids in Oral Fluid.

Authors:  Jeffrey R Enders; Gregory L McIntire
Journal:  J Anal Toxicol       Date:  2015-10       Impact factor: 3.367

2.  Plasma levels and cerebrospinal fluid penetration by duloxetine in a patient with a non-fatal overdose during a suicide attempt.

Authors:  Michael Paulzen; Christoph Hiemke; Gerhard Gründer
Journal:  Int J Neuropsychopharmacol       Date:  2009-08-06       Impact factor: 5.176

Review 3.  Adverse events, toxicity and post-mortem data on duloxetine: case reports and literature survey.

Authors:  Eric L Vey; Inna Kovelman
Journal:  J Forensic Leg Med       Date:  2010-03-19       Impact factor: 1.614

Review 4.  Duloxetine: clinical pharmacokinetics and drug interactions.

Authors:  Mary Pat Knadler; Evelyn Lobo; Jill Chappell; Richard Bergstrom
Journal:  Clin Pharmacokinet       Date:  2011-05       Impact factor: 6.447

5.  Effect of age on the pharmacokinetics of duloxetine in women.

Authors:  Michael H Skinner; Han-Yi Kuan; Andrej Skerjanec; Mary E Seger; Michael Heathman; Lisa O'Brien; Shobha Reddy; Mary P Knadler
Journal:  Br J Clin Pharmacol       Date:  2004-01       Impact factor: 4.335

6.  Comparison of molecularly imprinted solid-phase extraction (MISPE) with classical solid-phase extraction (SPE) for the detection of benzodiazepines in post-mortem hair samples.

Authors:  Robert A Anderson; Marinah M Ariffin; Peter A G Cormack; Eleanor I Miller
Journal:  Forensic Sci Int       Date:  2007-04-27       Impact factor: 2.395

7.  Non-fatal overdose of duloxetine in combination with other antidepressants and benzodiazepines.

Authors:  Marco Menchetti; Beatrice Ferrari Gozzi; Maria Addolorata Saracino; Laura Mercolini; Carmine Petio; Maria Augusta Raggi
Journal:  World J Biol Psychiatry       Date:  2009       Impact factor: 4.132

8.  The prevalence of duloxetine in medico-legal death investigations in Victoria, Australia (2009-2012).

Authors:  Jennifer L Pilgrim; Dimitri Gerostamoulos; Olaf H Drummer
Journal:  Forensic Sci Int       Date:  2013-11-20       Impact factor: 2.395

9.  Pharmacokinetics of duloxetine self-administered in overdose with quetiapine and other antipsychotic drugs in a Japanese patient admitted to hospital.

Authors:  Koichiro Adachi; Satoru Beppu; Kei Nishiyama; Makiko Shimizu; Hiroshi Yamazaki
Journal:  J Pharm Health Care Sci       Date:  2021-02-03

10.  Duloxetine treatment adherence across mental health and chronic pain conditions.

Authors:  Stephen L Able; Zhanglin Cui; Wei Shen
Journal:  Clinicoecon Outcomes Res       Date:  2014-02-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.